More than 18,000 doses of Nuvaxovid COVID-19 vaccine administered, 5 cases of severe reactions recorded

0

SINGAPORE: More than 18,000 doses of Novavax’s Nuvaxovid COVID-19 vaccine have been administered as of Aug 31, with five cases of severe side effects reported.

In its 13th vaccine safety report on Monday (Sep 19), the Health Sciences Authority said there were 28 reports of adverse reactions, of which 82 per cent – or 23 cases – were not serious.

This included allergic reactions such as rash and eye swelling, numbness, inflammation of blood vessels, dizziness and chest pain.

“These were largely consistent with what were reported in the clinical studies or with other COVID-19 vaccines,” HSA said. Common side effects that recipients may experience include injection site pain and/or tenderness, fatigue, headache and muscle pain.

HSA granted interim authorisation to the Nuvaxovid COVID-19 vaccine for use in individuals aged 18 and above in February, under the Pandemic Special Access Route. Singapore began administering the vaccine to the public on May 18.

Five cases of severe side effects have been reported as of Aug 31, including four cases of anaphylaxis and one case of a serious allergic reaction.

“These occurred in susceptible individuals who had previous allergic reactions or adverse effects to Pfizer/Comirnaty and Sinovac-CoronaVac COVID-19 vaccines, as well as a history of drug or food allergies,” HSA added.

“All the patients have recovered from the serious adverse reactions.”

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest For News Update Click Here 

Read original article here

Denial of responsibility! Rapidtelecast.com is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
Leave a comment